Blue light destroys antibiotic-resistant staph infection

Jan 29, 2009

Two common strains of methicillin-resistant Staphylococcus aureus, commonly known as MRSA, were virtually eradicated in the laboratory by exposing them to a wavelength of blue light, in a process called photo-irradiation that is described in a paper published online ahead of print in Photomedicine and Laser Surgery. The article will appear in the April 2009 issue (Volume 27, Number 2) of the peer-reviewed journal published by Mary Ann Liebert, Inc.

Antibiotic-resistant bacterial infections represent an important and increasing public health threat. At present, fewer than 5% of staphylococcal strains are susceptible to penicillin, while approximately 40%-50% of Staph aureus isolated have developed resistance to newer semisynthetic antibiotics such as methicillin as well.

Chukuka S. Enwemeka, Deborah Williams, Sombiri K. Enwemeka, Steve Hollosi, and David Yens from the New York Institute of Technology (Old Westbury, NY) had previously demonstrated that photo-irradiation using 405-nm light destroys MRSA strains grown in culture. In the current study, "Blue 470-nm Light Kills Methicillin-Resistant Staphylococcus aureus (MRSA) in Vitro," the authors exposed bacterial colonies of MRSA to various doses of 470-nm light, which emits no UV radiation.

The two MRSA populations studied—the US-300 strain of CA-MRSA and the IS-853 strain of HA-MRSA—represent prominent community-acquired and hospital-acquired strains, respectively.

The authors report that the higher the dose of 470-nm blue light, the more bacteria were killed. High-dose photo-irradiation was able to destroy 90.4% of the US-300 colonies and the IS-853 colonies. The effectiveness of blue light in vitro suggests that it should also be effective in human cases of MRSA infection, and particularly in cutaneous and subcutaneous infections.

"It is inspiring that an inexpensive naturally visible wavelength of light can eradicate two common strains of MRSA. Developing strategies that are capable of destroying MRSA, using mechanisms that would not lead to further antibiotic resistance, is timely and important for us and our patients," says Chukuka S. Enwemeka, PhD, FACSM, Co-Editor-in-Chief of the Journal and first author of the study.

The paper is available free online at www.liebertpub.com/pho.

Source: Mary Ann Liebert

Explore further: AMA: Gender inequality still exists in medicine

add to favorites email to friend print save as pdf

Related Stories

How red tide knocks out its competition

Jun 04, 2014

New research reveals how the algae behind red tide thoroughly disables – but doesn't kill – other species of algae. The study shows how chemical signaling between algae can trigger big changes in the ...

Recommended for you

New medical device to make the mines safer

Nov 21, 2014

Dehydration can be a serious health issue for Australia's mining industry, but a new product to be developed with input from Flinders University's Medical Device Partnering Program (MDPP) is set to more effectively ...

US family gets $6.75 million in Botox case

Nov 20, 2014

A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.